Ashfall forecast for Kirishima (Shinmoe-dake). It is at volcanic alert level 2, with ashfall expected to the northeast from 9 to 12 and from 21 to 24 on the 20th.
Volcanic alert level 2 remains in effect for Suwanosejima, and if an eruption occurs, ashfall is expected north of the crater from 9 to 12 on the 20th.
If an eruption occurs at Sakurajima, ashfall is expected northeast of the crater from 09 to 12 on the 20th. The volcano is currently at volcanic alert level 3 (restricted access to the mountain).
Mount Meakan is at volcanic alert level 2. Ashfall is expected to the southeast from 21 to 24 on the 19th and to the northeast from 09 to 12 on the 20th.
Volcanic alert level 3 remains in effect for Sakurajima, with ashfall expected to the northeast from 21 to 24 on the 19th and from 09 to 12 on the 20th.
Volcanic alert level 2 remains in effect for Suwanosejima. Ashfall is expected to the northwest from 21 to 24 on the 19th and to the northeast from 09 to 12 on the 20th.
Volcanic alert level 2 remains in effect for Suwanosejima. Ashfall is expected to the northwest from 21 to 24 on the 19th and to the north from 09 to 12 on the 20th.
Volcanic alert level 3 remains in effect for Sakurajima, with ashfall expected to the northeast from 21 to 24 on the 19th and from 09 to 12 on the 20th.
Ashfall forecast for Mount Meakan. It is at volcanic alert level 2, with ashfall expected to the southeast from 21 to 24 on the 19th and to the northeast from 09 to 12 on the 20th.
Volcanic alert level 2 remains in effect for Mount Aso. Ashfall is expected to the northeast from 21 to 24 on the 19th and to the east from 09 to 12 on the 20th.
The crater-area warning (eruption alert Level 3) remains in effect because eruptions accompanied by large volcanic blocks flying more than 1 km from Sakurajima's Minamidake summit crater and Showa crater, and small-scale pyroclastic flows, may occur.
Ashfall forecast for Mount Meakan. It is currently at volcanic alert level 2 (restrictions around the crater), with ashfall expected southeast of the crater from 21 to 24 on the 19th.
Published ・ Source Japan | 気象庁 ・ 2 identical notices
If an eruption occurs at Sakurajima, ashfall is forecast northeast of the crater from 21:00 to 24:00 on the 19th. The volcano is currently at Volcanic Alert Level 3 (restricted entry).
Ashfall forecast for Mount Meakan. The volcano is at Volcanic Alert Level 2, with ashfall forecast northeastward and southeastward during certain times on the 19th.
Ashfall forecast for Kirishima-yama (Shinmoedake). Volcanic Alert Level 2; ashfall is forecast in a northeasterly direction during specific time slots on the 19th.
信紘科(6667): Announces changes to its co-CEO, deputy general manager and corporate governance officer
Published ・ Source Taiwan | 公開資訊觀測站
信紘科(6667) announced that co-CEO, deputy general manager and corporate governance officer Wang Yiwen resigned on 115/10/19. A new corporate governance officer will be announced separately.
寶德(3349): Announces board resolution to convene an extraordinary shareholders' meeting in 115
Published ・ Source Taiwan | 公開資訊觀測站
寶德(3349) announced that its board resolved to convene an extraordinary shareholders' meeting on 115/12/11 in Xindian District, New Taipei City, to be held in person. The main agenda includes reporting accumulated losses reaching one-half of paid-in capital, a full re-election of directors (including independent directors), and lifting restrictions on the new directors' engagement in competing businesses. The share transfer suspension period is from 115/11/12 to 115/12/11.
Facts
1. Date of board resolution: 115/10/19
2. Date of extraordinary shareholders' meeting: 115/12/11
1st Floor, No. 28, Baogao Road, Xindian District, New Taipei City
Proposal on the company's accumulated losses reaching one-half of paid-in capital
9. Start date of share transfer suspension: 115/11/12
10. End date of share transfer suspension: 115/12/11
TLC-KY(7924): Announces provision of endorsements and guarantees pursuant to Article 25, Paragraph 1, Items 2, 3 and 4 of the Regulations Governing Loaning of Funds and Making of Endorsements and Guarantees by Public Companies
TLC-KY(7924): Announces provision of endorsements and guarantees pursuant to Article 25, Paragraph 1, Item 1 of the Regulations Governing Loaning of Funds and Making of Endorsements and Guarantees by Public Companies
TLC-KY(7924): Announces board resolution to establish a sustainability committee
Published ・ Source Taiwan | 公開資訊觀測站
TLC-KY(7924) announced that its board resolved to establish a sustainability committee. The new members are Chang Lan-ching, Yeh Chih-hung and Shih Hsueh-fang. The committee takes effect on 115/10/19.
安成生技(6610): Announces relevant financial and business information after its securities met the suspension-of-trading criteria under Article 11-1 of the 財團法人證券櫃檯買賣中心 Rules Governing the Trading of Emerging Stocks.
Published ・ Source Taiwan | 公開資訊觀測站
安成生技(6610) announced relevant financial and business information after its securities met the suspension-of-trading criteria under Article 11-1 of the 財團法人證券櫃檯買賣中心 Rules Governing the Trading of Emerging Stocks.
中光電投控(3718): Announces change in legal representatives at subsidiaries 蘇州璨宇光電有限公司 and 蘇州璨曜光電有限公司
Published ・ Source Taiwan | 公開資訊觀測站
中光電投控(3718) announced that Wang Yanlin will be replaced by Wu Hsieh-shih as the legal representative of its subsidiaries 蘇州璨宇光電有限公司 and 蘇州璨曜光電有限公司, effective 115/10/19.
TLC-KY(7924): Announces preliminary analysis of Phase 3 clinical trial of its long-acting postoperative pain drug TLC590 met the primary efficacy endpoint, with a statistically significant difference on the secondary efficacy endpoint compared with liposomal bupivacaine
Published ・ Source Taiwan | 公開資訊觀測站
TLC-KY(7924) announced preliminary results from the Phase 3 clinical trial of its long-acting postoperative pain drug TLC590, with both primary and secondary efficacy endpoints showing statistically significant differences. The company will proceed with a new drug application.
Facts
A total of 304 subjects who underwent bunion surgery in the United States were enrolled
2025 product net sales were approximately US$575 million
Acquisition of Pacira BioSciences, Inc. for a total equity value of approximately US$1.65 billion
Companies mentioned:TLC-KY、Pacira BioSciences, Inc.、Viatris Inc.
TLC-KY(7924): Announces contents of press release for a media briefing on material information
Published ・ Source Taiwan | 公開資訊觀測站
TLC BioSciences Corp. announced that the unblinded results of the Phase 3 clinical trial of its long-acting postoperative pain drug TLC590 showed statistical significance, and referred to competitor Pacira BioSciences and acquirer Viatris Inc.
Facts
A total of 304 subjects who underwent bunion surgery in the United States were enrolled
The groups included 100 people in the TLC590 group
102 people in the Exparel group and 102 people in the placebo group
The difference between groups was -73.54
p=0.0024
The median for the TLC590 group ... was 10
The median for the Exparel group was ... 15 milligrams
2025 product net sales were approximately US$575 million
Total equity value of approximately US$1.65 billion
Companies mentioned:TLC BioSciences Corp.、Pacira BioSciences, Inc.、Viatris Inc.
科建(7886) announced that General Manager Wen Chih-chi resigned for personal career planning, effective 115/10/19. The vice chairman will temporarily assume the role.
第一傳動(7957): Invited to attend the pre-emerging-stock listing investor conference hosted by 永豐金證券
Published ・ Source Taiwan | 公開資訊觀測站
第一傳動(7957) was invited to attend the pre-emerging-stock listing investor conference hosted by 永豐金證券 on 115/10/20 to discuss the company's operations and future outlook.
Original仁新*(6696):代重要子公司Belite Bio, Inc公告董事會決議通過升板 登錄那斯達克全球精選市場(Nasdaq Global Select Market)
Published ・ Source Taiwan | 公開資訊觀測站
仁新*(6696) announced that its material subsidiary Belite Bio, Inc received Nasdaq approval to move up from the 那斯達克資本市場 to 那斯達克全球精選市場 (Nasdaq Global Select Market) effective 115/10/19. Its ticker symbol will remain “BLTE.” The move is expected to improve its financial position, liquidity and visibility among institutional investors.
Facts
The company holds 41.95% of Belite Bio, Inc
Shareholding will be diluted to 36.23%
The shareholding will be diluted to 35.37%
Date of occurrence: 115/10/19
Ticker symbol remains “BLTE”
Companies mentioned:仁新*、Belite Bio, Inc、Nasdaq、那斯達克資本市場、那斯達克全球精選市場、那斯達克股票交易所、Nasdaq Biotechnology Index
中光電投控(3718): Announces acquisition of ordinary shares of 中光創業投資股份有限公司 contributed by subsidiary 中強光電股份有限公司 through a return of capital in kind
Published ・ Source Taiwan | 公開資訊觀測站
中光電投控 announced that it acquired ordinary shares of 中光創投 contributed by its subsidiary 中強光電 through a return of capital in kind, for a total transaction amount of approximately NT$308 million.
中光電投控(3718): Announces acquisition of ordinary shares of 中光電智能雲服股份有限公司 contributed by subsidiary 中強光電股份有限公司 through a return of capital in kind
Published ・ Source Taiwan | 公開資訊觀測站
中光電投控 announced that it acquired ordinary shares of 中光電智能雲服 contributed by its subsidiary 中強光電 through a return of capital in kind, involving 25,000,000 shares and a total transaction amount of approximately NT$381 million.
中光電投控(3718): Announces acquisition of common shares of 中光電智能機器人股份有限公司 surrendered by subsidiary 中強光電股份有限公司 through a capital reduction in kind
Published ・ Source Taiwan | 公開資訊觀測站
中光電投控 announced that it acquired common shares of 中光電智能機器人 surrendered by its subsidiary 中強光電 through a capital reduction in kind, in a transaction valued at approximately NT$653 million.
中光電投控(3718): Announces, on behalf of subsidiary 中強光電股份有限公司, a capital reduction and surrender of common shares of 中光創業投資股份有限公司
Published ・ Source Taiwan | 公開資訊觀測站
中光電投控(3718) announced that its subsidiary 中強光電 surrendered its holdings of common shares of 中光創業投資 to its parent, 中光電投資控股股份有限公司, through a capital reduction in kind.
中光電投控(3718): Announces, on behalf of subsidiary 中強光電股份有限公司, a capital reduction and surrender of common shares of 中光電智能雲服股份有限公司
Published ・ Source Taiwan | 公開資訊觀測站
中光電投控(3718) announced that its subsidiary 中強光電 surrendered 25 million common shares of 中光電智能雲服 to its parent, 中光電投資控股股份有限公司, through a capital reduction in kind, in a transaction valued at approximately NT$380 million.
中光電投控(3718): Announces, on behalf of subsidiary 中強光電股份有限公司, a capital reduction and surrender of common shares of 中光電智能機器人股份有限公司
Published ・ Source Taiwan | 公開資訊觀測站
中光電投控(3718) announced that its subsidiary 中強光電 surrendered its holdings of common shares of 中光電智能機器人 to its parent, 中光電投資控股股份有限公司, through a capital reduction.
中光電投控(3718): Announces board resolution on capital reduction at subsidiary 中強光電股份有限公司
Published ・ Source Taiwan | 公開資訊觀測站
中光電投控(3718), on behalf of its subsidiary 中強光電, announced a board resolution on a capital reduction. Equity interests in three wholly owned subsidiaries and some cash will be returned to the parent company. The capital reduction will total NT$1.9 billion, with a reduction ratio of 48.60%.
藍新資訊(6938): Announces collection of unpaid employee subscription payments for its cash capital increase before its initial TPEx listing
Published ・ Source Taiwan | 公開資訊觀測站
藍新資訊 announced that it will collect unpaid employee subscription payments for its cash capital increase before its initial TPEx listing. The collection period runs from 115年10月20日至115年11月20日15時30分.
京晨科(6419): Announcement that the Company's cumulative acquisition of securities over the past year has reached the disclosure threshold
Published ・ Source Taiwan | 公開資訊觀測站
京晨科 announced that its cumulative acquisitions of marketable securities over the past year reached the reporting threshold. The transaction involved 台灣積體電路製造股份有限公司, with 13,521 shares acquired for a total of NT$32,453 thousand.
前源(3601): Announces resignation of independent directors
Published ・ Source Taiwan | 公開資訊觀測站
前源(3601) announced that independent directors 周朝國 and 蔡安地 resigned on 115/10/19, effective 115/11/30. The change represents 2/7 of the original term, and the company will hold a by-election at an extraordinary shareholders' meeting.
Facts
Director turnover rate during the same term: 2/7
Date of change: 115/10/19
Original term: 114/06/17
117/06/16
Effective date of independent director resignation: 115/11/30
竟天(6917): At least half of the shares available for subscription in the company's 115-year cash capital increase were waived by directors; company to approach specific persons for subscriptions
Published ・ Source Taiwan | 公開資訊觀測站
竟天(6917) announced that directors waived subscription rights for at least half of the shares available in its 115-year cash capital increase, and authorized the chairman to approach specific persons to subscribe.
Facts
Shares waived from subscription: 125,336
Percentage of shares available for subscription: 86.24%.
Shares waived from subscription: 461,528
Percentage of shares available for subscription: 100.00%.
普生(4117): Announces receipt of letter from auditor stating it will not continue the engagement
Published ・ Source Taiwan | 公開資訊觀測站
普生(4117) announced that its former auditor, 資誠聯合會計師事務所, initiated the decision not to continue the engagement. Discussions with a new auditor are underway.
程曦資訊(6898): Announces details of its overallotment before its initial TPEx listing
Published ・ Source Taiwan | 公開資訊觀測站
程曦資訊整合股份有限公司 announced details of the overallotment for its initial TPEx listing. The underwriting price is NT$60.00 per share, the public offering comprises 3,289,000 shares, and both the overallotment shares and proceeds are 0.
程曦資訊(6898): Announces collection of unpaid employee subscription payments for its cash capital increase before its initial TPEx listing
Published ・ Source Taiwan | 公開資訊觀測站
程曦資訊(6898) announced that it will collect unpaid employee subscription payments for its cash capital increase before its initial TPEx listing. The collection period runs from 115年10月20日起至115年11月20日下午3時30分止.
光聚晶電(6111): Correction to the 115/9/8 announcement regarding its subsidiary's disclosures under Article 22, Paragraph 1, Subparagraphs 2 and 3 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
欣大健康(4198): Announces receipt of full payment for its first domestic secured convertible corporate bond issue
Published ・ Source Taiwan | 公開資訊觀測站
欣大健康投資控股股份有限公司 announced that it has received the full proceeds from its first domestic secured convertible corporate bond issuance, totaling NT$306,133,900.